Miracle Shot Silences Snoring And Knee Pain

White tablets spilling from a plastic bottle — Photo: anek jaikui / Shutterstock

A diabetes-free weight loss drug just cut knee arthritis pain and sleep apnea symptoms by numbers doctors call clinically remarkable.

Story Snapshot

Eli Lilly’s experimental drug retatrutide sharply reduced knee osteoarthritis pain in a large Phase 3 trial called TRIUMPH-1.
The same drug cut sleep apnea severity by more than 30 events per hour in people with moderate to severe disease.
Results come from a program testing more than 5,800 participants across four global trials.
Retatrutide is not approved anywhere yet, and these benefits appear alongside major weight loss.
The findings fit a broader pattern of obesity drugs easing conditions once treated as separate diseases.

Pain Scores Dropped Far Below the Threshold Doctors Watch

Lilly’s TRIUMPH-1 trial measured knee pain using a standard scoring tool called the WOMAC scale. Patients on 9 milligram and 12 milligram doses of retatrutide saw their pain scores fall by 3.5 and 3.6 points, compared to 1.9 points for those on placebo. Both results were statistically strong, with Lilly reporting a probability value under.001 for each comparison.

That gap matters because researchers set a bar for what counts as a real improvement, not just a statistical blip. Lilly says the pain reduction cleared a widely used clinical threshold of 4 points once baseline pain levels are factored in. From a starting average pain score of 6.0, some patients saw drops as steep as 73 percent.

Knee osteoarthritis affects millions of older adults and is a leading reason people eventually need joint replacement surgery. A drug that meaningfully reduces that pain without surgery or daily medication juggling would change how doctors manage a condition that has few effective treatments beyond physical therapy and pain relievers.

Breathing Trouble Eased by More Than Half During Sleep

The sleep apnea results followed a similar pattern. Patients with moderate to severe obstructive sleep apnea who took retatrutide saw their apnea-hypopnea index, a measure of how often breathing stops or slows during sleep, fall by 34.3 events per hour on the 9 milligram dose and 31.7 on the 12 milligram dose. The placebo group dropped by just 9.9 events.

Lilly says those reductions beat a clinically meaningful threshold of 15 events per hour, meaning the improvement was not a marginal number dressed up to look impressive. From an average starting point of 58.6 events per hour, some patients saw their breathing interruptions cut by more than 60 percent.

A Trial Built From the Start to Test More Than Obesity

These results did not come from a side observation tacked onto a weight loss study. Lilly designed the TRIUMPH program specifically to test retatrutide across multiple conditions tied to obesity, running four separate global trials that began in 2023 and enrolled more than 5,800 people, with dedicated groups for knee osteoarthritis and sleep apnea built in from the start.

That structure matters because it means researchers tracked these outcomes with the same rigor used for weight loss itself, using randomized, double-blind methods where neither patients nor doctors knew who received the real drug. It is the kind of evidence base regulators expect before considering new treatment uses.

Part of a Wider Shift in How Weight Loss Drugs Are Viewed

Retatrutide is not the only drug in this category showing effects beyond the scale. Tirzepatide, sold as Zepbound, already demonstrated apnea-hypopnea reductions in earlier trials, and semaglutide has shown it can ease knee pain and improve physical function using the same WOMAC scoring system used in Lilly’s trial. Researchers increasingly view obesity drugs as treatments for the diseases obesity causes, not just the weight itself.

New clinical trial data suggest Eli Lilly's once-a-day GLP-1 pill, Foundayo, could help treat obstructive sleep apnea—further expanding the potential uses of these drugs beyond weight losshttps://t.co/7dS8vAW1C1

— Scientific American (@sciam) November 9, 2026

Retatrutide remains investigational, meaning it has not been approved for sale anywhere in the world, and these results have not yet translated into an official treatment label. Regulators will still need to review safety data across Lilly’s broader development program before doctors can prescribe it for arthritis pain or sleep apnea specifically, rather than weight loss alone.